Albumin for hyperacute stroke: another failed neuroprotectant

Affiliations

¹ Stroke Trials Unit, Division of Clinical Neuroscience, University of Nottingham, City Hospital campus, Nottingham NG5 1PB, UK. Electronic address: philip.bath@nottingham.ac.uk.

Comment

Philip M W Bath. Lancet Neurol. 2013 Nov.

. 2013 Nov;12(11):1036-7.

doi: 10.1016/S1474-4422(13)70212-6. Epub 2013 Sep 27.

¹ Stroke Trials Unit, Division of Clinical Neuroscience, University of Nottingham, City Hospital campus, Nottingham NG5 1PB, UK. Electronic address: philip.bath@nottingham.ac.uk.

No abstract available

Comment on

High-dose albumin treatment for acute ischaemic stroke (ALIAS) Part 2: a randomised, double-blind, phase 3, placebo-controlled trial.
Ginsberg MD, Palesch YY, Hill MD, Martin RH, Moy CS, Barsan WG, Waldman BD, Tamariz D, Ryckborst KJ; ALIAS and Neurological Emergencies Treatment Trials (NETT) Investigators. Ginsberg MD, et al. Lancet Neurol. 2013 Nov;12(11):1049-58. doi: 10.1016/S1474-4422(13)70223-0. Epub 2013 Sep 27. Lancet Neurol. 2013. PMID: 24076337 Free PMC article. Clinical Trial.